Japan cancer biomarkers market is growing at a CAGR of around 11.9% during the forecast period. Japan market for biomarkers is expected to witness positive growth during forecast period. The mortality rate in Japan due to cancer is increasing day by day. The reason for mortalities due to cancer tobacco smoking. The increasing prevalence of cancer holds a promising market for biomarkers in Japan for the treatment of cancers. In 2017, there were around 1.1 million cases of cancer were registered in which 149,500 cases were of colon cancer followed by 132,800 cases of stomach cancer and 128,700 cases of lung cancer. 

Visit for Global Cancer Biomarker Market Report at: https://www.omrglobal.com/industry-reports/cancer-biomarkers-market

Further, the mortality due to cancer in Japan is estimated to around 0.37 million in 2017, which is also affecting the Japan cancer biomarker market growth. According to the Tsugane’s contribution to cancer research, the population attributable fraction (PAF) of tobacco smoking to cancer was 24%, infection was 22%, alcohol drinking was 6%, and over-intake of salt was 1.4%. The causes of the other 50% of cancer death were not sufficiently clarified. Also studied the PAF for cancer incidence and found that it is almost the same as that for cancer death.

In June 2017, Immunovia was granted a patent for biomarker signature for pancreatic cancer diagnosis. This was done for the success of IMMray PanCan-d test in Japan which is a commercial market for Immunovia. Safeguard R&D investment in such novel diagnostic tests Effective patent protection is vital in order. Additionally, in August 2017, Biomarker Strategies received two patent approvals, one for Snap Path and other for PathMAP technologies. Japan is in need to develop more targeted disease detection and treatments for a rapidly growing patient population, augmenting the market for Japan cancer biomarkers.

Research Methodology

The market study of the Japan cancer biomarker market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report is intended for biotechnology companies, research laboratories, pharmaceutical companies, research institutions, hospitals, and other related companies for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Japan Cancer Biomarker Market Research and Analysis by Biomarker Type

2. Japan Cancer Biomarker Market Research and Analysis by Cancer Type

3. Japan Cancer Biomarker Market Research and Analysis by Application

4. Japan Cancer Biomarker Market Research and Analysis by Profiling Technology

The Report Covers

• Comprehensive research methodology of the Japan Cancer biomarker market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the Japan Cancer biomarker market.
• Insights about market determinants which are stimulating the Japan Cancer biomarker market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.